Elecsys Phospho-Tau (217P) Plasma
Roche Diagnostics · Decision date Aug 19, 2026
What did the FDA decide?
FDA records K261686 as a 510(k) premarket notification, with a decision dated Aug 19, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Immunology
- Decision date
- Aug 19, 2026
Regulatory record facts
- Identifier
- K261686
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roche Diagnostics
- Product code
- SET
- Decision code
- SESE
- Decision date
- Aug 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunoassay Blood Test For Amyloid Pathology Assessment.
- Applicant
- Roche Diagnostics
- Product code
- SET
- FDA device class
- 2
FDA decision timeline
K261686 received
Application receipt date recorded by FDA.
K261686 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code SET
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PrecivityAD2 TestK253240 | C2N Diagnostics, LLC | 510(k) clearance | Aug 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianapolis, IN
Sources and methodology
- Original FDA record: K261686
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records